PFG Advisors Sells 3,261 Shares of Eli Lilly and Company $LLY

Key Points

• PFG Advisors cut its stake in Eli Lilly by 44.9%, selling 3,261 shares and leaving it with 4,007 shares valued at $4.306 million at quarter-end.
• Analysts have largely raised targets and reiterated bullish views—MarketBeat shows a consensus rating of “Moderate Buy” with an average price target of $1,225.33, and several firms setting targets up to $1,350.
• Eli Lilly posted strong quarterly results (EPS $7.54, revenue $19.29B) and gave FY2026 EPS guidance of 33.50–35.00, but the stock is under pressure due to weaker early uptake of its obesity pill and mixed GLP‑1 prescription data, posing near‑term sentiment risk.

PFG Advisors reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 44.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,007 shares of the company's stock after selling 3,261 shares during the quarter. PFG Advisors' holdings in Eli Lilly and Company were worth $4,306,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. 10Elms LLP raised its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. raised its holdings in Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after buying an additional 10 shares during the period. Tanager Wealth Management LLP raised its holdings in Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after buying an additional 10 shares during the period. Bridgewater Advisors Inc. raised its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company's stock valued at $3,018,000 after buying an additional 11 shares during the period. Finally, Manske Wealth Management raised its holdings in Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company's stock valued at $342,000 after buying an additional 11 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. BMO Capital Markets restated an "outperform" rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Daiwa Securities Group increased their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. Bank of America increased their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a "buy" rating in a report on Thursday, April 2nd. Barclays assumed coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price target on the stock. Finally, CICC Research increased their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,225.33.

Eli Lilly and Company Stock Down 3.6%

NYSE:LLY opened at $884.88 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a market cap of $836.05 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51. The stock has a fifty day simple moving average of $958.83 and a 200-day simple moving average of $983.91. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. The business's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 33.9 EPS for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly's obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.